New PML cases overshadow strong Elan results

After Elan reported better than expected results last week, the spectre of brain disease progressive multifocal leukoencephalopathy (PML) once again threw a shadow over the company’s multiple sclerosis drug, Tysabri, last Friday.

24th October, 2009

After Elan reported better than expected results last week, the spectre of brain disease progressive multifocal leukoencephalopathy (PML) once again threw a shadow over the company’s multiple sclerosis drug, Tysabri, last Friday.

The European Medicines Agency announced that 23 cases of PML had been confirmed since the drug was launched, sending shares down by as much as 20 per cent. The previous update on PML cases in mid-September indicated that there had been 13 cases.

The...

Subscribe from just €1 for the first month!

Currency

What's Included

With any subscription you will have access to

  • 971569B3-2C5E-4C45-B798-CEADE16987A8

    Unlimited multi-device access to our iPad, iPhone and Android Apps

  • 099C8662-C57C-42F2-9426-F2F90DF17C8F

    Unlimited access to our eReader library

  • 198AE43B-B9CF-4892-8769-D63C2104BA08

    Exclusive daily insight and opinion seven days a week

  • D8F37B78-25E4-4E4A-A376-4F5789B1564A

    Create alerts to never miss a subject that matters to you

  • B15F2521-37CD-4E02-B898-730A20D39F7F

    Get access to exclusive offers for subscribers on gifts and experiences

  • A564FE02-1AB8-4579-AF9D-BA32A2E5ACA7

    Get content from Business Post, Business Post Magazines, Connected, Tatler and Food & Wine

Share this post

Related Stories

The year in review

Legacy Richie Oakley 1 year ago

Newsround: What Thursday’s papers say

Legacy Leanna Byrne 6 years ago

More cycle routes, expansion of Luas to Bray and new bus network proposed

Legacy Digital Desk 6 years ago